Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals Inc
(NQ:
TARS
)
25.96
+0.65 (+2.57%)
Streaming Delayed Price
Updated: 11:28 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tarsus Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday
July 20, 2023
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
July 18, 2023
Via
Benzinga
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
December 15, 2022
Via
Benzinga
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
June 12, 2023
Webcast scheduled for Thursday, June 15 at 8:30am PT
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at the Jefferies Global Healthcare Conference
June 05, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
May 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
May 08, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
May 03, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
April 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
March 13, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
March 02, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
February 23, 2023
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...
Via
Benzinga
Tarsus Added to NASDAQ Biotechnology Index
December 16, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
November 09, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 25, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Transition Plans for Board of Directors
October 11, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
October 06, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
September 29, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
August 01, 2022
Upgrades
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
May 03, 2022
Tuesday's session saw 211 companies set new 52-week lows.
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
31 Stocks Moving In Monday's Mid-Day Session
May 02, 2022
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...
Via
Benzinga
66 Biggest Movers From Yesterday
May 03, 2022
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Looking Into Tarsus Pharmaceuticals's Return On Capital Employed
March 16, 2022
According to Benzinga Pro data, during Q4, Tarsus Pharmaceuticals (NASDAQ:TARS) posted sales of $338.00 thousand. Earnings were up 5.39%, but Tarsus Pharmaceuticals still reported...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 20, 2022
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.